期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌患者TRβ1基因甲基化与新辅助化疗疗效敏感性的观察 被引量：1

原文传递
导出
摘要 目的观察乳腺癌患者中甲状腺素受体β1(TRβ1)基因甲基化状态与CTF(环磷酰胺+吡柔吡星+氟尿嘧啶)新辅助化疗方案敏感性的关系。方法采用半巢式甲基化特异性PCR(MSP)技术检测40例乳腺癌患者及20例健康体检者血清中TRβ1基因甲基化状态;依据TRβ1基因不同甲基化状态将40例乳腺癌患者分为甲基化组及未甲基化组,比较两组对CTF新辅助化疗方案的敏感性。结果 40例乳腺癌患者中,26例TRβ1基因异常甲基化(65.0%),20例健康体检者检测到TRβ1基因未出现异常甲基化,两者差异有统计学意义(P<0.05);乳腺癌患者未甲基化组对CTF化疗方案的敏感性为78.6%(11/14),甲基化组的敏感性为34.6%(9/26),未甲基化组的敏感性高于甲基化组,差异有统计学意义(P<0.05)。结论 TRβ1基因甲基化状态有望作为乳腺癌选用CTF新辅助化疗方案的敏感性依据之一。
作者 令亚琴 张茜 汪泳 令晓玲
机构地区 兰州大学基础医学院病理生理学研究所 兰州军区兰州总医院 兰州大学第一医院肿瘤内科
出处 《四川大学学报（医学版）》 CAS CSCD 北大核心 2010年第6期1063-1064,1079,共3页 Journal of Sichuan University(Medical Sciences)
基金 甘肃省科技厅支撑项目(项目编号:090NKCA126)资助
关键词 乳腺癌 新辅助化疗 疗效 TRβ1甲基化
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1陈灿铭,沈镇宙.乳腺癌新辅助化疗疗效预测因子的研究现状[J].循证医学,2007,7(3):132-134. 被引量：9
  • 2Ling YQ, Xu XY, Hao J, et al. Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients. Cancer Gen,2010; 196(1) :140-145.
  • 3Yang HJ, Liu VW, Wang Y, et al. Detection of hypermethy/ated genes in tumor and plasma of cervical cancer patients. Gyneeol Oneol,2004,93(2) :435-440.
  • 4乳腺癌的新辅助化疗.林华主编.第1版.北京:人民军医出版社,2006:173-194.
  • 5Chea RN, Huang YH, Yeh CT, et al. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Res,2008,68(2):1697-1706.
  • 6Uigon CJ, Cheng SY. Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol Cell Endocrinol, 2009; 308 ( 12 ) : 63- 69.
  • 7Li Z, Meng ZH, Chandrasekaran R, et al. BiaUelic inactivation of the thyroid hormone receptor β1 gene in early stage breast cancer. Cancer Res,2002,62(20):1943-1939.
  • 8Liedtke C, Mazouni C, Kenneth SS, et al. Response to neoadjuvant therapy andlong-term survival in patients with triple-negative breast cancer . Clin Oncol, 2008,26 (8) : 1275- 1281.
  • 9SanchezoMunoz A, Garcia-Tapiador AM, et al. Tumour molecularsubtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol, 2008 , 10 (10) : 646-653.

二级参考文献16

  • 1Fisher ER,Wang J,Bryant J,et al.Pathobiology of preoperative chemotherapy findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18[J].Cancer,2002,95:681-695.
  • 2Schneeweiss A,Katretchko J,Sinn HP,et al.Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy[J].Anticancer Drugs,2004,15(2):127-135.
  • 3Colleoni M,Minchella I,Mazzarol G,et al.Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptor[J].Ann Oncol,2000,11:1-3.
  • 4MacGrogan G,Mauriac L,Durand M,et al.Primary chemotherapy in breast invasive carcinoma:predictive value of the immuno-histochemical detection of hormonal receptors,p53,c-erbB-2,MiB1,pS2 and GST pi[J].Br J Cancer,1996,74:1458-1465.
  • 5Mieog JS,van der Hage JA,van de Vijuer MJ,et al.Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer:The predictive role of p53 expression[J].Eur J Cancer,2006,42(10):1369-1379.
  • 6Munoz-Gonzalez D,Zeichner-Gancz I,Candelaria M,et al.Her-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a mexican population of locally advanced breast cancer patients[J].Med Oncol,2005,22(1):23-28.
  • 7Martin-Richard M,Munoz M,Albanell J,et al.Serial topoisomerase Ⅱ expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy[J].Oncology,2004,66 (5):388-394.
  • 8Chevillard S,Pouillart P,Beldjord C,et al.Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy[J].Cancer,1996,77(2):292-300.
  • 9Kostler WJ,Steger GG,Soleiman A,et al.Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer[J].Anticancer Res,2004,24 (2C):1127-1130.
  • 10Demiray M,Ulukaya EE,Arslan M,et al.Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product,caspase-cleaved cytokeratin 18:A prospective pilot study[J].Cancer Invest,2006,24 (7):669-676.

共引文献8

同被引文献12

引证文献1

二级引证文献3

四川大学学报（医学版）
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部